Healthcare stocks took a 4.65% hit over the past week along with many growth stocks. The Nasdaq (QQQ) was also down about 4.5% in one of the worst sell-off weeks of the year. The DIA was flattish and cyclicals continue to lead the way with the S&P 500 Energy index up 10.6%, Financials up 5.36% and Commodity indices showing strength. We are looking for a biotech boost this week from the JPMorgan Healthcare Conference and the beginning of the pivotal earnings season. Many Companies will present news updates and guidance for 2022 and some analysts believe January sets the pace for the year. But the Fed commentary last week convinced many growth investors that higher interest rates in a good economy favor value stocks. Many small and mid cap biotech stocks are overvalued and with a banner year in IPOs it is harder to pick the winners.

Image Source: Unsplash

Here are some of our large cap picks to watch for updates on Day One: Bristol-Myers (BMY) a laggard at $62.83 with a 3.51% div,, Regeneron (REGN) recently sold off to $603.73 but we expect news to boost the stock, Vertex Pharmaceuticals (VRTX)  with a nice rally to $221.85, one of our best recent picks.

Several other large cap biopharma  companies are presenting on Monday: Biogen (BIIB), Gilead Sciences (GILD), Moderna (MRNA), Pfizer (PFE) and Merck (MRK).